Kyverna Therapeutics (NasdaqGS:KYTX) FY Conference January 14, 2026 12:45 PM ET Company ParticipantsWarner Biddle - CEONone - Video NarratorNone - TranslatorConference Call ParticipantsNone - Analyst 3None - Analyst 1None - Analyst 4Brian Cheng - Senior Biotech AnalystNone - Analyst 2Brian ChengGood morning. Thank you so much for joining us for another session at the 44th JPMorgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here at the firm. On stage, we have Kyverna Therapeut ...

Sana Biotechnology (NasdaqGS:SANA) FY Conference January 14, 2026 12:45 PM ET Company ParticipantsSteve Harr - President and CEOConference Call ParticipantsTess Romero - Senior Biotech AnalystTess RomeroWelcome, everyone, to the 44th Annual J.P. Morgan Healthcare Conference. My name is Tess Romero, and I'm one of the Senior Biotech Analysts here at J.P. Morgan. Our next presenting company is Sana. And presenting on behalf of the company, we have President and CEO Steve Harr. Steve, over to you.Steve HarrTha ...

Establishment Labs (NasdaqCM:ESTA) FY Conference January 14, 2026 12:45 PM ET Company ParticipantsRaj Denhoy - CFOPeter Caldini - CEOConference Call ParticipantsNone - AnalystNoneOkay. Thanks, everyone, for being here. I'm really excited to be introducing some of the management team from Establishment Labs. We're going to be starting off with a presentation from CEO Peter Caldini, and then Raj Denhoy, CFO, will be joining us for some Q&A afterwards.Peter CaldiniGreat. Thank you. Thank you very much. It's a ...

Bioventus (NasdaqGS:BVS) FY Conference January 14, 2026 12:45 PM ET Company ParticipantsMark Singleton - SVP and CFO \Robert Claypoole - CEOConference Call ParticipantsNone - AnalystNoneGood morning, everyone. Welcome, thank you for joining us. My name is David Brumund. I'm an associate on the healthcare team at J.P. Morgan, and today I have the pleasure of introducing the Bioventus team. Joining us today is CEO Rob Claypoole and CFO Mark Singleton. Just a quick reminder on format: this will be a 20-minute ...

Nova (NasdaqGS:NVMI) FY Conference January 14, 2026 12:45 PM ET Company ParticipantsGuy Kizner - CFOConference Call ParticipantsNone - AnalystNoneAll right, good afternoon. This is the 28th Annual Needham Growth Conference. Joining me on the stage is from Nova. I'm thrilled to have Guy Kizner, the CFO, here on the stage with me. Thank you for joining today. I believe this is your second time at this conference.Guy KiznerRight.Yeah.Thank you, Charles. It's really great to be here. We very appreciate the fact ...

Partners Group (OTCPK:PGPH.F) Update / briefing January 14, 2026 12:15 PM ET Company ParticipantsDavid Layton - CEORoberto Cagnati - Partner, Chief Risk Officer and Head of Portfolio SolutionsJoris Groflin - CFOConference Call ParticipantsGregory Simpson - Senior Equity AnalystHubert Lam - Director and Senior Equity Research AnalystMate Nemes - Senior Equity Research AnalystNicholas Herman - Director and Equity Research AnalystOperatorGood day, and thank you for standing by. Welcome to the Partners Group's ...

Omada Health FY Conference Summary Company Overview - **Company**: Omada Health (NasdaqGS:OMDA) - **Industry**: Digital Health and Chronic Disease Management - **Mission**: To bend the curve of disease and improve care for chronic disease patients, particularly those with obesity, diabetes, and other related conditions [3][4] Key Highlights Financial Performance - **Revenue**: $257 million for FY 2025, representing a **52% year-over-year growth** [6][26] - **Members Supported**: 886,000 active members [7][26] - **Adjusted Gross Margin**: Upper 60s% for LTM Q3 2025, improved from the 50s% in 2022 [26] - **Adjusted EBITDA Margin**: -2.4% for LTM Q3 2025, improved from nearly -70% in 2022, with the first positive adjusted EBITDA quarter of $2.4 million in Q3 2025 [27] Market Position and Strategy - **Target Market**: Over 20 million Americans covered by Omada's programs through 2,000+ customers, including self-insured employers and health plans [5][18] - **Expansion**: Initially focused on prediabetes and obesity, now expanded to diabetes, hypertension, and musculoskeletal (MSK) care [6][9] - **Growth Drivers**: - Multi-product offerings, including the new GLP-1 Care Track [21] - Customer-driven expansion based on demand for comprehensive care solutions [9][19] Product and Service Offerings - **Care Model**: Combines technology and personalized care to support patients between doctor visits [5][10] - **GLP-1 Care Track**: Launched to provide behavioral support alongside GLP-1 medications, addressing concerns about medication adherence and effectiveness [21][22] - **Engagement Metrics**: Over 55% of members remain engaged after 12 months, and 50% after two years [14][15] Clinical and Economic Outcomes - **Clinical Evidence**: 30 peer-reviewed publications demonstrating the effectiveness of Omada's programs [15][16] - **Economic Value**: Expected ROI of 3-6x in musculoskeletal care, with gross healthcare savings of $1,000-$1,500 per member [16][26] Future Outlook - **Investment Focus for 2026**: Emphasis on AI initiatives and enhancing prescribing capabilities to drive long-term growth and margin expansion [41][42] - **Market Trends**: Increased focus on chronic disease management from government and employers, with potential opportunities in Medicare Advantage [54][56] - **Customer Demand**: Growing interest in combining prescribing with behavioral management for chronic conditions [43][44] Additional Insights - **Customer Relationships**: Strong demand for multi-product solutions, with 75% of new clients opting for more than one condition [52] - **Regulatory Environment**: Positive dialogue with government regarding chronic disease management, indicating potential for future partnerships [54][56] - **Technological Integration**: Use of AI to enhance member experience and operational efficiency, with features like nutritional intelligence agents [38][39] This summary encapsulates the key points from Omada Health's FY conference, highlighting the company's growth, strategic direction, and the evolving landscape of chronic disease management.

Larimar Therapeutics (NasdaqGM:LRMR) FY Conference January 14, 2026 12:00 PM ET Company ParticipantsCarole Ben-Maimon - President and CEOConference Call ParticipantsHenry Jiang - AnalystHenry JiangToday, my name is Henry Jiang. I'm with the banking team here at JPMorgan, and it's my pleasure to introduce Larimar Therapeutics today. Presenting today will be Dr. Carole Ben-Maimon, President and CEO of Larimar. Just a quick note: we'll have time for Q&A after the presentation, so please wait until then for any ...

Concentra Group Holdings Parent (NYSE:CON) FY Conference January 14, 2026 12:00 PM ET Company ParticipantsMatthew DiCanio - CFOTanner Newton - SVP of Finance and StrategyKeith Newton - CEOConference Call ParticipantsBenjamin Rossi - AnalystBenjamin RossiAll right. Thank you all. First and foremost, thank you all for joining us here in person, and for those who are joining us via webcast. My name is Ben Rossi, and I'm the Healthcare Facilities Analyst here at J.P. Morgan. We are excited to welcome Concentra ...

CytomX Therapeutics FY Conference Summary Company Overview - **Company**: CytomX Therapeutics (NasdaqGS:CTMX) - **Industry**: Oncology-focused biotechnology - **Location**: South San Francisco - **Key Personnel**: - Sean McCarthy (CEO) - Chris Ogden (CFO) - Rachel Lester (Chief Business Officer) - Wayne Chu (Chief Medical Officer) Core Points and Arguments Pipeline and Technology - CytomX has developed a unique Probody therapeutic platform aimed at masking antibodies to improve therapeutic windows in oncology [3][4] - The company is focused on two main clinical programs: - **Vasetatag masatikan (Vaseta M)**: An EpCAM-targeting Probody Topo-1 ADC for colorectal cancer [3][5] - **CX801**: A Probody version of interferon alpha-2b for melanoma [3][6] Financial Position - CytomX is well-funded, with cash reserves extending into Q2 2027, excluding potential milestones or new business developments [4] Vaseta M Program - The phase one study for Vaseta M is expanding to over 100 patients, with data updates expected by the end of Q1 2026 [8][19] - Initial data showed a 28% confirmed overall response rate and 94% disease control in late-line colorectal cancer patients [14][17] - The market for colorectal cancer is significant, with 1.9 million patients diagnosed annually, projected to exceed 3 million by 2040, and a $5 billion market opportunity in the U.S. for late-line treatment [10][22] Safety and Efficacy - Vaseta M demonstrated a favorable safety profile with no classic EpCAM toxicities, which have historically limited other EpCAM-targeting therapies [15][18] - The most common adverse event reported was grade 3 diarrhea, occurring in 21-22% of patients, which the company is actively investigating [19][36] Future Development Plans - CytomX aims to initiate a combination study of Vaseta M with bevacizumab to explore earlier lines of treatment [20][30] - The company plans to expand into other tumor types where EpCAM is expressed, potentially leading to a pan-tumor agnostic label [21][22] CX801 Program - CX801 is being developed as a novel immunotherapy for melanoma, particularly in patients who have progressed on checkpoint inhibitors [23][26] - The program aims to harness the activity of interferon alpha-2b while minimizing systemic toxicity through masking strategies [24][25] - Initial data from the combination with Keytruda is expected by the end of 2026 [30] Additional Important Content - CytomX has established partnerships with major pharmaceutical companies, including BMS, Amgen, and Moderna, enhancing its business development capabilities [4] - The company emphasizes the importance of understanding the etiology of adverse events, particularly gastrointestinal toxicities, to optimize patient management [37][38] - The strategic decision to focus on colorectal cancer was based on the abundance of the EpCAM target and the unmet medical need in this area [40][41] Conclusion CytomX Therapeutics is positioned at the forefront of innovation in oncology with its differentiated pipeline and strategic focus on unmet needs in colorectal cancer and melanoma. The upcoming data releases and ongoing studies are critical for validating the efficacy and safety of its lead programs, which could significantly impact the treatment landscape in these areas.